Share Price | Neumora Therapeutics, Inc. Stock Analysis & Recommendation

Q: How big is Neumora Therapeutics, Inc.?

Market Cap: As of Jun 18, Neumora Therapeutics, Inc. has a market capitalization of 128.27 million, categorizing it as a Small Cap company.Recent Quarterly Performance: For the latest four quarters, Neumora Therapeutics, Inc. reported net sales of 0.00 million and a net profit of -258.06 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 287.06 million and total assets of 316.97 million.

Q: What does Neumora Therapeutics, Inc. do?

Overview: Neumora Therapeutics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a small-cap company.Financial Snapshot: Net Profit: -68 Million (Quarterly Results - Mar 2025) Market Cap: USD 128.27 Million (Small Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.09 Return on Equity: -113.00% Price to Book: 0.56Contact Details: Details: No Company Details Available Registrar Address: Not available.

Q: Is Neumora Therapeutics, Inc. technically bullish or bearish?

As of 8 September 2025, the technical trend for Neumora Therapeutics, Inc. has changed from sideways to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD shows no signal. The Bollinger Bands suggest a mildly bullish outlook on the weekly chart but are bearish on the monthly. Daily moving averages are bearish, and the KST is bullish on the weekly but shows no trend monthly. The Dow Theory reflects a mildly bullish trend weekly with no trend monthly, while the OBV is mildly bearish across both time frames.The stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -85.19% versus the S&P 500's 12.22%, and a one-year return of -87.14% compared to 17.14% for the benchmark. Overall, the technical stance is mildly bearish, driven by the bearish daily moving averages and mixed signals from other indicators.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

798.35 k

Shareholding (Sep 2025)

FII

19.07%

Held by 72 FIIs

DII

55.01%

Held by 20 DIIs

Promoter

14.81%

How big is Neumora Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Neumora Therapeutics, Inc. has a market capitalization of 128.27 million, with net sales of 0.00 million and a net profit of -258.06 million over the latest four quarters. The company reported shareholder's funds of 287.06 million and total assets of 316.97 million as of Dec 24.

View full answer

What does Neumora Therapeutics, Inc. do?

22-Jun-2025

Neumora Therapeutics, Inc. is a small-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $68 million and a market cap of $128.27 million. Key financial metrics include a negative P/E ratio, a debt-to-equity ratio of -1.09, and a return on equity of -113%.

View full answer

Is Neumora Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 8, 2025, Neumora Therapeutics, Inc. exhibits a mildly bearish technical trend, with daily moving averages bearish and mixed signals from other indicators, significantly underperforming the S&P 500 with year-to-date and one-year returns of -85.19% and -87.14%, respectively.

View full answer

Compare Neumora Therapeutics, Inc. with Similar Stocks

Harmony Biosciences Holdings, Inc.Xenon Pharmaceuticals, Inc.Amphastar Pharmaceuticals, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 326 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.15

Return on Equity

-175.01%

Price to Book

2.47

Revenue and Profits:

Net Sales:

(Quarterly Results - Sep 2025)

Net Profit:

-57 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-29.75%

6 Months

18.79%

1 Year

2.62%

2 Years

-87.24%

3 Years

0.0%

4 Years

0.0%

5 Years

0.0%

Neumora Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-62.02%

EBIT to Interest (avg)

-205.08

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.09

Sales to Capital Employed (avg)

34.92

Tax Ratio

0.11%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

55.34%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.72

EV to EBIT

0.31

EV to EBITDA

0.31

EV to Capital Employed

3.98

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

1290.10%

ROE (Latest)

-113.00%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Dow Theory

Mildly Bullish

No Trend

OBV

Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 35 Schemes (11.11%)

Foreign Institutions

Held by 72 Foreign Institutions (19.07%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 21.66% vs -36.79% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-52.70",
          "val2": "-76.50",
          "chgp": "31.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.70",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-5.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-56.80",
          "val2": "-72.50",
          "chgp": "21.66%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -3.35% vs -80.21% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-262.80",
          "val2": "-187.50",
          "chgp": "-40.16%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-63.90",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-243.80",
          "val2": "-235.90",
          "chgp": "-3.35%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Sep'25

Sep'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-52.70

-76.50

31.11%

Interest

0.70

0.00

Exceptional Items

-5.00

0.00

Consolidate Net Profit

-56.80

-72.50

21.66%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024

Consolidated Net Profit

YoY Growth in quarter ended Sep 2025 is 21.66% vs -36.79% in Sep 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-262.80

-187.50

-40.16%

Interest

0.00

Exceptional Items

0.00

-63.90

100.00%

Consolidate Net Profit

-243.80

-235.90

-3.35%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -3.35% vs -80.21% in Dec 2023

All Annual Results

Company CV

About Neumora Therapeutics, Inc.

Neumora Therapeutics, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Neumora Therapeutics, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Neumora Therapeutics, Inc.?

Watch in Real-Time

What does Neumora Therapeutics, Inc. do?

Is Neumora Therapeutics, Inc. technically bullish or bearish?

Compare Neumora Therapeutics, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Neumora Therapeutics, Inc.

Company Coordinates